Codexis, Inc.CDXS

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · codexis.com

Codexis is a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, leveraging its proprietary CodeEvolver technology to discover, develop and enhance novel high-performance enzymes. Its enzymes address challenges in small molecule pharmaceuticals manufacturing and nucleic acid synthesis, and the company is developing its ECO Synthesis manufacturing platform to enable scaled enzymatic manufacture of RNAi therapeutics.

Key ratios

FCF / Sales

-33.9%2025

2024 -90.5%2023 -81.3%

Net margin

-39.6%TTM

2025 -62.5%2024 -110.0%2023 -108.7%

ROA

-16.1%2025

2024 -25.5%2023 -17.7%

ROE

-69.4%TTM

2025 -74.9%2024 -85.0%2023 -65.9%

Revenue growth

35.9%TTM

2025 18.6%2024 -15.4%2023 -49.4%

Recent news

Codexis Announces Pricing of Public Offering of Common Stock 2026-07-24 · GlobeNewswire

Track CDXS in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer